About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Advice For Those Trying High-Throughput Screening | Main | Roche Repurposes »

November 28, 2012

Every Tiny Detail

Email This Entry

Posted by Derek

Via Chemjobber, we have here an excellent example of how much detail you have to get into if you're seriously making a drug for the market. When you have to account for every impurity, and come up with procedures that generate the same ones within the same tight limits every time, this is the sort of thing you have to pay attention to: how you dry your compound. And how long. And why. Because if you don't, huge amounts of money (time, lost revenue, regulatory trouble, lawsuits) are waiting. . .

Comments (5) + TrackBacks (0) | Category: Analytical Chemistry | Chemical News | Drug Development


1. Anonymous on November 28, 2012 3:59 PM writes...

"An efficient synthesis of the known 1-(1-methylpiperidin-
4-yl)piperazine 4 was developed" looks wrong to me.....

Permalink to Comment

2. Helical_Investor on November 28, 2012 4:08 PM writes...

#1 - There are two links in the first part of Derek's post.

As to the Chemjobber post, yeah, 'never put anything flush on the metal floor of the drying oven' is an early lesson everyone should learn prior to industry, but don't always.


Permalink to Comment

3. processchemist on November 29, 2012 3:48 AM writes...

And in this case there's no problem about particle size distribution variation and polymorphs switch during drying... There's not only the impurity formation problem, but the constant bioavailability issue too...
A TGA/DSC analysis can be of great help in setting the drying conditions for products with problems during standard drying (the classical case: "I obtained this wonderful cake of white crystals, why they turned yellow on drying?").

Permalink to Comment

4. Anonymous on November 29, 2012 5:40 AM writes...

for a multi billion dollar market and highly skilled employees this is not really something to brag about... no wait, why again is this kinf of quality and reliability unkown in clinical medicine or IT?

Permalink to Comment

5. Optimization colleague on November 29, 2012 7:41 AM writes...

Welcome to the world of process chemistry. Getting into this kind of detailed optimization involves some highly skilled scientific endeavours and strong collaboration between synthetic, physical organic and analytical chemists and engineers. You need to really underestand what's going on and then define conditions where you get the desired product to the desired yield and quality every time. Exciting stuff! And a completley different world to medicinal chemistry...

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry